Dr. Rahel Demisse, MD

Dr. Demisse practices at Riverside University Medical Center in Moreno Valley, California.

Dr. Demisse's NPI, 1124462486, was assigned on April 17, 2013. Dr. Demisse graduated from Keck School of Medicine of USC in 2013. Dr. Demisse holds California license A135179.

Dr. Demisse's primary practice is Riverside University Medical Center, at 26520 Cactus Ave, Moreno Valley, CA 92555 in Riverside County. The practice phone is (951) 486-4458.

Dr. Demisse's primary practice is Riverside University Medical Center in Moreno Valley, California. Dr. Demisse is also affiliated with Riverside University Health System - Medical Center. The medical group on file is Loma Linda University Faculty Medical Group (LLUFMG).

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Demisse practices. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Demisse's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Demisse is board certified in hematology by the American Board of Internal Medicine. Dr. Demisse is licensed in California.

Dmand AI lists breast cancer, colorectal cancer, lung cancer, lymphoma, multiple myeloma and prostate cancer among the conditions Dr. Demisse treats.

CMS data shows 219 Medicare services from Dr. Demisse across 4 procedure codes in 2024, for 53 Medicare patients. Medicare paid $7,745 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 53 Medicare patients who saw Dr. Demisse in 2024. The largest group is 65 to 74, with 28 patients. 75% of them have cancer, and 75% have high blood pressure. Their average risk score is 2.82, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Demisse's median patient age at 61, with 50% women.

In 2024, Dr. Demisse wrote 164 Medicare Part D claims for 33 patients. 70% of them were for generic drugs. CMS names the drug for 101 of them, across 5 drugs with 11 or more claims each, at $399,828 in total drug cost. In 2023, CMS named 108 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Demisse for performance year 2024, reported as part of a group. Dr. Demisse accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 22 general payments to Dr. Demisse from 16 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 77% of the total. Millennium Pharmaceuticals, Inc. paid the most, $186.

Dr. Demisse graduated from Keck School of Medicine of USC in 2013.

Dr. Demisse is in network with 15 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.